Home » All News » Cancer Epidemiology Biomarkers & Prevention: Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers

Cancer Epidemiology Biomarkers & Prevention: Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers

Published On: May 11, 2012
Shared by Brian Phillips

Amanda B Spurdle¹, Louise Marquart, Lesley McGuffog, Sue Healey, Olga Sinilnikova, Fei Wan, Xiaoqing Chen, Jonathan Beesley, Christian F Singer, Anne-Catharine Dressler, Daphne Gschwantler-Kaulich, Joanne L Blum, Nadine Tung, Jeff Weitzel, Henry Lynch, Judy Garber, Douglas F Easton, Susan Peock, Margaret Cook, Clare T Oliver, Debra Frost, Don Conroy, D Gareth Evans, Fiona Lalloo, Ros Eeles, Louise Izatt, Rosemarie Davidson, Carol Chu, Diana Eccles, Christina G Selkirk, Mary Daly, Claudine Isaacs, Dominique Stoppa-Lyonnet, Olga M Sinilnikova, Bruno Buecher, Muriel Belotti, Sylvie Mazoyer, Laure Barjhoux, Carole Verny-Pierre, Christine Lasset, Hélène Dreyfus, Pascal Pujol, Marie-Agnès Collonge-Rame, GEMO Study Collaborators; Matti A Rookus, Senno Verhoef, Mieke Kriege, Nicoline Hoogerbrugge, Margreet G E M Ausems, Theo A van Os, Juul Wijnen, Peter Devilee, Hanne E J Meijers-Heijboer, Marinus J Blok, Tuomas Heikkinen, Heli Nevanlinna, Anna Jakubowska, Jan Lubinski, Tomasz Huzarski, Tomasz Byrski, Francine Durocher, Fergus J Couch, Noralane M Lindor, Xianshu Wang, Mads Thomassen, Susan Domchek, Kate Nathanson, Ma Caligo, Helena Jernström, Annelie Liljegren, Hans Ehrencrona, Per Karlsson, SWE-BRCA; Patricia A Ganz, Olufunmilayo I Olopade, Gail Tomlinson, Susan Neuhausen, Antonis C Antoniou, Georgia Chenevix-Trench, Timothy R Rebbeck

Abstract

Background: Inherited BRCA1 and BRCA2 (BRCA1/2) mutations confer elevated breast cancer risk. Knowledge of factors that can improve breast cancer risk assessment in BRCA1/2 mutation carriers may improve personalized cancer prevention strategies.

Methods: A cohort of 5,546 BRCA1 and 2,865 BRCA2 mutation carriers were used to evaluate the risk of breast cancer associated with BARD1 Cys557Ser. In a second nonindependent cohort of 1,537 BRCA1 and 839 BRCA2 mutation carriers, BARD1 haplotypes were also evaluated.

Results: The BARD1 Cys557Ser variant was not significantly associated with risk of breast cancer from single SNP analysis, with a pooled effect estimate of 0.90 (95% CI: 0.71-1.15) in BRCA1 carriers and 0.87 (95% CI: 0.59-1.29) in BRCA2 carriers. Further analysis of haplotypes at BARD1 also revealed no evidence that additional common genetic variation not captured by Cys557Ser was associated with breast cancer risk.

Conclusion: Evidence to date does not support a role for BARD1 variation, including the Cy557Ser variant, as a modifier of risk in BRCA1/2 mutation carriers.

Impact: Interactors of BRCA1/2 have been implicated as modifiers of BRCA1/2-associated cancer risk. Our finding that BARD1 does not contribute to this risk modification may focus research on other genes that do modify BRCA1/2-associated cancer risk.

Article Categories: All News, Research Paper

Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, and accelerate the translation of knowledge into novel therapies. Greehey CCRI strives to have a national and global impact on childhood cancer by discovering, developing, and disseminating new scientific knowledge. Our mission consists of three key areas — research, clinical, and education.

Stay connected with the Greehey CCRI on Facebook, Twitter, LinkedIn, and Instagram.